Nabla Bio, a next-generation antibody design company, announced the closing of a $11M Seed financing round. The round was co-led by Khosla Ventures and Zetta Venture Partners, with participation from Fifty Years, Cantos Ventures, and others.

Nabla Bio is an antibody design company. The company’s AI-first protein design platform enables rapid engineering of best-in-class antibody therapeutics. The foundational technology was developed by CEO Surge Biswas, academic Co-Founder George Church and their team at Harvard, and has advanced the field of machine learning-guided protein modeling and design. The company has a fully functional wet lab to complement its machine learning capabilities. Nabla Bio is based in Boston, MA. For additional information, please visit www.nabla.bio.

Nabla Bio Closes $11M Seed Financing Led By Khosla Ventures And Zetta Venture Partners

Nabla Bio Closes $11M Seed Financing Led By Khosla Ventures And Zetta Venture Partners

Company Info